An Open Phase II, Multi Center Trial of BAY 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria:

- Measurable disease as defined by the presence of at least one measurable lesion

- Failed at least one prior therapy or has achieved remission but has progressed or
relapsed within 6 months of therapy

- Life expectancy of at least 12 weeks

- Adequate bone marrow, liver and kidney function

Exclusion Criteria:

- Excluded medical conditions like: pre-existing neuropathy, active heart diseases or
ischemia, serious infections, HIV infection, chronic hepatitis B or C, seizures,
hypersensitivity to taxanes, organ transplants, some previous cancers

- Excluded therapies and medications, previous and concomitant such as: anticancer
chemotherapy or immunotherapy during the study or within 4 weeks prior to study
entry; more than two prior anticancer chemotherapy regimens; radiotherapy during
study or within 4 weeks prior to study entry; bone marrow transplant

- Others: pregnant or breast-feeding patients; both men and women enrolled in this
trial must use adequate barrier birth control measures during the course of the
trial; substance abuse, medical, psychological or social conditions that may
interfere with the patient's participation